Laurie Curtis

Vice President, Head of Clinical Operations at Nordic Nanovector Asa

Laurie Curtis's Professional Contact Details

Email (Verified)

****

Get Email Address

+47 22 18 33 01

Location

Chineham, England, United Kingdom

Company

Nordic Nanovector Asa

Person Seniority

Person Functions

operations

Laurie Curtis's Current Company Details

Nordic Nanovector Asa

Oslo, Oslo, Norway • 35 Employees

biotechnology

Nordic Nanovector's mission is to extend and improve the lives of patients with haematological cancers by developing and commercialising innovative Antibody Radionuclide Conjugates (ARC). The Company's lead clinical-stage product opportunity is BetalutinÂ®, the first in a new class of Antibody-Radionuclide-Conjugates (ARCs) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities. BetalutinÂ® comprises a tumour-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It has shown promising efficacy in Phase 1 studies in a difficult-to-treat NHL patient population as well as favourable tolerability. The Company aims to rapidly develop BetalutinÂ® for the treatment of major types of NHL with first regulatory submission in follicular lymphoma (FL) anticipated 1H 2019.

Founded Year

2009

Organization Website

nordicnanovector.com

Organization Languages

English

Organization Revenue

5200

Current Technologies

incapsula

google analytics

apache